Eli Lilly (NYSE:LLY) faces new lawsuits alleging its GLP-1 drug Mounjaro causes irreversible vision loss linked to NAION. Regulators in several countries issued safety updates on GLP-1 eye risks while...
Source LinkEli Lilly (NYSE:LLY) faces new lawsuits alleging its GLP-1 drug Mounjaro causes irreversible vision loss linked to NAION. Regulators in several countries issued safety updates on GLP-1 eye risks while...
Source Link
Comments